BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31701556)

  • 1. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
    Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
    EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
    Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
    Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
    Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
    Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
    Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
    Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
    Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
    Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
    Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
    J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
    Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX
    Eur J Neurosci; 2009 Dec; 30(12):2271-83. PubMed ID: 20092570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic temporal lobe epilepsy is associated with enhanced Alzheimer-like neuropathology in 3×Tg-AD mice.
    Yan XX; Cai Y; Shelton J; Deng SH; Luo XG; Oddo S; Laferla FM; Cai H; Rose GM; Patrylo PR
    PLoS One; 2012; 7(11):e48782. PubMed ID: 23155407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice.
    Cuddy LK; Alia AO; Salvo MA; Chandra S; Grammatopoulos TN; Justman CJ; Lansbury PT; Mazzulli JR; Vassar R
    Mol Neurodegener; 2022 Aug; 17(1):54. PubMed ID: 35987691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
    Zhao J; Fu Y; Yasvoina M; Shao P; Hitt B; O'Connor T; Logan S; Maus E; Citron M; Berry R; Binder L; Vassar R
    J Neurosci; 2007 Apr; 27(14):3639-49. PubMed ID: 17409228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation.
    Cai Y; Xiong K; Zhang XM; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Chu Y; Kordower JH; Yan XX
    Eur J Neurosci; 2010 Oct; 32(7):1223-38. PubMed ID: 20726888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease.
    Liang B; Duan BY; Zhou XP; Gong JX; Luo ZG
    J Biol Chem; 2010 Sep; 285(36):27737-44. PubMed ID: 20595388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
    Andrew RJ; Fernandez CG; Stanley M; Jiang H; Nguyen P; Rice RC; Buggia-Prévot V; De Rossi P; Vetrivel KS; Lamb R; Argemi A; Allaert ES; Rathbun EM; Krause SV; Wagner SL; Parent AT; Holtzman DM; Thinakaran G
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9665-E9674. PubMed ID: 29078331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1.
    Wang X; Wang Y; Hu JP; Yu S; Li BK; Cui Y; Ren L; Zhang LD
    Mol Neurobiol; 2017 May; 54(4):2939-2949. PubMed ID: 27023226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
    Sadleir KR; Eimer WA; Cole SL; Vassar R
    Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
    Sadleir KR; Eimer WA; Kaufman RJ; Osten P; Vassar R
    PLoS One; 2014; 9(7):e101643. PubMed ID: 24992504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
    Ly PT; Wu Y; Zou H; Wang R; Zhou W; Kinoshita A; Zhang M; Yang Y; Cai F; Woodgett J; Song W
    J Clin Invest; 2013 Jan; 123(1):224-35. PubMed ID: 23202730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.
    McConlogue L; Buttini M; Anderson JP; Brigham EF; Chen KS; Freedman SB; Games D; Johnson-Wood K; Lee M; Zeller M; Liu W; Motter R; Sinha S
    J Biol Chem; 2007 Sep; 282(36):26326-34. PubMed ID: 17616527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.